World Biosimilar Congress 2016

In 2015, we saw the crescendo of the Amgen versus Sandoz case after many months of appeals. Along with that legal case, many more are still ongoing in the biosimilar sector. This year also provided a milestone in the ongoing discussions and debates on naming conventions with both the US FDA and WHO providing their individual guidance on such issues.

But what does all this mean for future biosimilar development?

Many questions need answering in order for biosimilars to reach the market success that the industry knows it can attain.

Category: Conferences | Science, Health & Medicine | Pharmaceuticals

URL:
Booking: https://go.evvnt.com/59128-1

Price:
Final standard price : £1980,
Final academic price : £990

Speakers: Dr Uwe Gudat, Head of Safety, Biosimilars, Merck, Mr Steiner Madsen, Medical Director, Norwegian Medicines Agency, Dr Mark McCamish, Global Head Biopharm.& Oncology Injectables Development, Sandoz, Mr Cecil Nick, Vice President, PAREXEL Mr Cecil Nick at World Biosimilar Congress, Michael Reilly, Executive Director, Alliance for Safe Biologic Medicines, Dr Steffen Thirstrup, Director, NDA Regulatory Advisory Board, NDA Advisory Services Ltd